National and Kapodistrian University of Athens
Ο ρόλος του παράγοντα νέκρωσης όγκων (tumor necrosis factor, TNF) και του ινοβλάστη στις πνευμονικές παθήσεις
Abstract
dc:descriptionIdiopathic Pulmonary Fibrosis (IPF) with the histopathologic pattern of UIP is a progressive and lethal pulmonary disease of unknown etiology. Despite the increased research focus, the accurate molecular mechanisms driving disease development remain largely unknown. This fact is also reflected by the inefficiency of current clinical practices to battle the disease, both at the level of prognosis and treatment. Careful observation of the fibrotic lung in combination with the failure of antiinflammatory and immunosuppressive factors to cure the disease, shifted research from the study of the immune parameters of the disease, towards the investigation of alternative molecular mechanisms that occur in alveolar epithelial cells and fibroblasts. Current research suggests that the mechanisms driving IPF reflect abnormal, deregulated wound healing, involving increased activity and possibly exaggerated responses by a spectrum of proinflammatory and profibrogenic factors that occur in sites of alveolar epithelial injury. Tumor Necrosis Factor (TNF) is a pleiotropic cytokine expressed by many cell types in response to infection or injury. TNF affects multiple responses that extend well beyond its well characterized pro-inflammatory properties to include diverse signals for cellular differentiation, proliferation and death; its functions can be both beneficial, as well as detrimental. Despite the apparent involvement of TNF in IPF development, research in the past few years failed to detect a specific role for TNF in the pathogenesis of IPF, while only isolated cases assessing anti-TNF efficacy for the treatment of the disease were reported in the literature. To decipher the role of TNF in the mechanisms underlying disease development and to explore the possible differential usage of its two forms as well as its two receptors, we used the Bleomycin-induced pulmonary fibrosis model and a series of genetically modified mice lacking components of TNF signaling. Transmembrane TNF expression was shown to be sufficient to elicit an inflammatory response, but inadequate for the transition to the fibrotic phase of the disease. Soluble TNF expression, further localized in apoptotic alveolar epithelial cells, was shown to be crucial for lymphocyte recruitment, a prerequisite for TGF-bl expression and the development of fibrotic lesions. These results suggest a primary detrimental role of soluble TNF in the pathologic cascade, separating it from the beneficial role of transmembrane TNF, and indicate the importance of assessing the efficacy of soluble TNF antagonists in the treatment of Idiopathic Pulmonary Fibrosis. Moreover, specific blockade of soluble TNF would be predicted to abolish the detrimental pro-fibrotic effects of TNF, while maintaining sufficient host defense against infections. Although anti-TNF treatment is unlikely to cure the disease (as in the case of rheumatoid arthritis and Crohn’s disease), it would still offer symptomatic relief and quality of life improvement. IPF represents a multifactorial entity with the involvement of many genes and molecular pathways in disease’s pathogenetic mechanisms. In an attempt to discover novel genes and/or cellular pathways that modify the pathogenesis of the disease and to indicate new therapeutic targets, gene expression profiling of disease progression was performed with the use of DNÀ microarrays. After rigorous statistical analysis differentially expressed genes were compared with all publicly available expression profiles both from human patients and animal models, thus creating a prioritized gene list of high statistical significance, consisted of the most likely disease modifiers identified so far in pulmonary fibrosis. Two of these genes HIF-la and GSN were chosen for further study in BLM-induced fibrosis. Hypoxia, the lack of oxygen, can modulate alveolar epithelial cell homeostasis by promoting significant and adverse effects on epithelial function, including VEGF and surfactant protein production, disruption of cytoskeleton integrity, the triggering of apoptosis and the induction of inflammation. HIF-la is recognized as a master regulator of hypoxic signaling by activating gene transcription of genes encoding proteins that mediate the cellular adaptive response under hypoxic conditions. Using immunohistochemical techniques upregulated expression of HIF-la and its major gene target VEGF were confirmed in the lungs of BLM-injected mice. Moreover, with the use of tissue microarrays, HIF-la and p53 expression was investigated in lung samples from patients with IPF/UIP and COP/OP, two histopathologic patterns of pulmonary fibrosis with different clinical course and prognosis. HIF-la expression in IPF was localized to the apoptotic alveolar epithelium and not in fibroblast foci, in which decreased apoptosis was found at least in part due to increased expression of the anti-apoptotic bcl-2 gene. This pattern of HIF-la expression was not observed in COP samples that increased production of HIF-la was found both in the epithelium and in areas with active fibrosis (Masson bodies). The differential expression of the HIF-la-p53 apoptotic axis within fibroproliferative areas in IPF and COP lung may explain the differences in clinical course, prognosis or treatment responsiveness between these two interstitial lung diseases. GSN (GSN) is an actin-binding protein that modulates cytoskeletal dynamics and has been implicated in caspase-mediated apoptosis. Its expression has been found deregulated in various transformed states affecting cellular proliferation and motility. Increased GSN expression was detected in modeled pulmonary inflammation and fibrosis. Genetically modified mice lacking GSN were shown to be protected from the development of pulmonary inflammation and fibrosis due to impaired neutrophil infiltration and decreased epithelial apoptosis. Cellular dissection of disease development suggested caspase-3-mediated fragmentation of GSN as a marker of alveolar epithelial apoptosis and the primary pathogenetic insult of modeled pulmonary inflammation and fibrosis. Moreover, GSN expression was also examined in lung samples of 65 human IIP patients (IPF, f-, c-NSIP, COP) impeded in tissue microarrays (TMA). The increased expression of GSN in IPF’s and f-NSIP’s alveolar epithelium but not in c-NSIP and COP may explain or even predict the differences in disease progression and treatment responsiveness. Collectively, the data presented in the doctoral dissertation, revealed new aspects of TNF biology in the context of IPF, discriminating the beneficial action of the transmembrane form from the deleterious action of the soluble form, suggesting that specific pharmacological targeting of solTNF could be proved useful for the treatment of the disease. Moreover and for the first time in the literature, the data provide evidence for the involvement of hypoxia/HIF-la and the cytoskeleton/GSN in the pathogenesis of IPF, indicating new perspectives for the design of novel therapeutic strategies.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Oikonomou, Nikos
- Οικονόμου, Νικόλαος
Subjects
dc:subject × 18- Πνεύμονες
- Ίνωση
- Μπλεομυκίνη
- Επιθήλιο
- Απόπτωση επιθηλιακών κυττάρων
- Φλεγμονές
- Ποντικοί, Διαγενετικά τροποποιημένοι
- Idiopathic pulmonary fibrosis (IPF)
- Bleomycin
- Expression profiling
- Apoptosis
- Tumor necrosis factor (TNF)
- Hypoxia inducible factor 1α
- Gelsolin ( GSN)
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/18703